






European Federation of Pharmaceutical
Industries and Associations

EFPIA Japan



Organization



EFPIA Japan committee activities (September 2023)

EFPIA Japan is focusing on the following activities

1. Put forth evidence-based policy recommendations to ensure appropriate reward for innovation and incentives for investment in research and development in the course of pricing reform discussions. **(Pricing and Economics Committee)**
2. Promote public-private dialogue on healthcare systems, including cost-effectiveness assessment aligned with the pricing system, diagnosis procedure combination per-diem payment (DPC), cancer genomic profiling and companion diagnostics, and intractable disease control, to improve patient access to medicines and ensure appropriate reward for innovation in the country. **(Access Committee)**
3. Support the improvement of a healthcare environment for patients by encouraging the activation of patient group activities, so that their voices are appropriately reflected in the healthcare system. Strengthen collaboration with patient groups in various disease areas through information exchanges and educational opportunities. **(Patient Committee)**
4. Contribute to improving the regulatory environment and the environment for executing drug development and post-marketing activities in Japan and enhancing development and evaluation technologies to ensure the availability of innovative medicines as quickly as possible with appropriate information and their safe use by patients. **(Technical Committee)**

5. Contribute to the further enhancement of compliance and integrity in the pharmaceutical industry and enable member companies to respond flexibly to changes from legal, ethical, and compliance perspectives.
(Governance and Legal Committee)
6. Develop and implement strategic advocacy plans in collaboration with other committees/working teams and other pharmaceutical industry bodies to advocate the importance of appropriate rewards for innovation and improvement of the regulatory environment to ensure patient access to innovative medicines in the country as quickly as possible. Create impactful and consistent messages that harmonize with all committees/working teams and promote EFPIA's policies. **(Messaging and Advocacy Committee)**
7. Develop and execute effective communication activities to advance EFPIA Japan's positions and initiatives, enhance its presence, and promote policy advocacy, thereby facilitating stakeholders' understanding.
(Communications Committee)
8. Contribute to the public health of the country by introducing world-class innovative vaccines to Japan as early as possible. Aiming to improve the predictability of the vaccine market in Japan, continue dialogue and collaboration with government and academia, and put forth policy recommendations to policymakers on regulations, including biological product standards and national assay, life-long immunization program, and awareness-raising on vaccination and infectious disease control. **(Vaccines Working Team)**
9. Promote patient access and regulatory harmonization for blood products through dialogue with the government. Enhance EFPIA Japan's presence and position as a trusted partner for blood law stakeholders.
(Blood Products Working Team)

EFPIA Japan key activities in 2022

EFPIA Japan offers a patient group support program “PASE”

Patient Advocacy Support by EFPIA Japan (PASE) is our initiative to support further development of the healthcare environment surrounding patients by encouraging revitalization of patient group activities in Japan so that their voice is appropriately reflected. We will make our best efforts to ensure “patient-centered healthcare” in Japan by supporting patient groups that contribute to development.



5th PASE award ceremony (October 5, 2022)